文献速递精神分裂症与精神病性障碍

抗精神病药所致镇静不良事件的轨迹:急性期精神分裂症随机安慰剂对照临床试验的个体参与者数据Meta分析

The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

该Meta分析纳入19项急性期精神分裂症或分裂情感障碍的安慰剂对照随机试验、6791例参与者,评估抗精神病药所致镇静的发生与缓解动态。582例(8.6%)出现镇静不良事件,接受抗精神病药者505例镇静事件中418例(83%)发生于治疗前2周;镇静发生后50%在1周内缓解,治疗4周后口服药者24%(95%CI 19.7-29.3)仍有镇静、长效针剂者22.3%(95%CI 15.3-32.3)仍有镇静。

要点

  • 抗精神病药治疗前2周内镇静发生率高,强调早期监测的重要性。
  • 镇静发生后50%在1周内缓解,75%在1个月内缓解,提示耐受形成较快。
  • 若镇静持续存在,应评估相关 contributing 因素。

核心结论

  • 抗精神病药治疗前2周内镇静发生率高,强调早期监测的重要性。
  • 半数镇静在1周内缓解、75%在1个月内缓解,提示镇静耐受形成较快。
  • 若镇静持续存在,应评估相关 contributing 因素。

研究设计与样本

  • 研究类型为个体参与者数据Meta分析,纳入急性期精神分裂症或分裂情感障碍的安慰剂对照随机对照试验中的抗精神病药单药治疗。
  • 检索PubMed自建库至2021年5月6日的随机对照试验,并通过耶鲁大学开放数据获取项目获得个体参与者数据。
  • 共纳入19项随机对照试验、6791例参与者(4549例[67.0%]男性、2242例[33.0%]女性,平均年龄38.0岁[SD 12.4,范围13-81],1172例[17.3%]亚洲人、1626例[23.9%]黑人、3654例[53.8%]白人、339例[5.0%]其他族裔)。
  • 采用Kaplan-Meier曲线评估治疗开始后不同时间镇静的发生概率与缓解概率。
  • 研究注册于PROSPERO,注册号CRD42022351647。

主要发现

  • 6791例参与者中582例(8.6%)观察到镇静不良事件,通常发生于治疗开始后不久。
  • 接受抗精神病药者505例镇静事件中418例(83%)发生于治疗前2周内。
  • 镇静发生后50%的症状在1周内缓解。
  • 治疗4周后,口服药者24%(95%CI 19.7-29.3)仍有镇静,长效针剂者22.3%(95%CI 15.3-32.3)仍有镇静。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sedative adverse events are common in patients with schizophrenia undergoing antipsychotic treatment, which affects treatment adherence and the patients' quality of life. Although tolerance to sedation is believed to develop, robust evidence documenting the timing of sedation onset and resolution remains elusive. To address this gap, we aimed to assess the dynamics of onset and resolution of sedation across various antipsychotics in patients with schizophrenia. METHODS: In this meta-analysis, we included placebo-controlled, randomised controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder. We searched PubMed for RCTs from inception until May 6, 2021 and obtained individual participant data of included trials through the Yale University Open Data Access project. We created Kaplan-Meier curves to assess the probability of onset of sedation and resolution from the incidence of sedation across time after treatment initiation. People with lived experience were not involved in this study. This study is registered with PROSPERO, CRD42022351647. FINDINGS: We included a total of 6791 participants (4549 [67·0%] men and 2242 [33·0%] women, with a mean age of 38·0 years [SD 12·4, range 13-81], 1172 [17·3%] were Asian, 1626 [23·9%] were Black, 3654 [53·8%] were White, and 339 [5·0%] were other ethnicities) from 19 RCTs. Sedative adverse events were observed in 582 (8·6%) of 6791 participants and typically occurred shortly after treatment initiation. Among participants receiving antipsychotics, 418 (83%) of 505 sedation events occurred within the first 2 weeks of treatment. Following the onset of sedation, 50% of symptoms were resolved within 1 week. After 4 weeks of treatment, 24% (95% CI 19·7-29·3) continued to have sedation with oral agents and 22·3% (15·3-32·3) with long-acting injectables. INTERPRETATION: The high incidence of sedation within the first 2 weeks of treatment with antipsychotics emphasises the importance of early monitoring. Half of the sedation resolved within 1 week and 75% within 1 month, suggesting that tolerance to sedation is acquired quickly. If sedation is sustained, contributing factors should be evaluated. FUNDING: German Federal Ministry of Education and Research.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Nomura N, Siafis S, Schneider-Thoma J, et al. The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase schizophrenia. Lancet Psychiatry. 2025. PMID: 40113354. doi:10.1016/S2215-0366(25)00025-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。